There are accumulating evidences that question the CSC nature of CD133+ population in several cancers, including colon cancer, glioma, and lung cancer, as CD133− population initiated long term tumors in vivo in these studies (Shmelkov et al., 2008; Irollo and Pirozzi, 2013). This evidence concerns the gene PROM1 and cancer.